skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: ScienceDirect Journals remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib)
Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib)

Martinón-Torres, Federico ; Boisnard, Florence ; Thomas, Stéphane ; Sadorge, Christine ; Borrow, Ray

Vaccine, 2017-06, Vol.35 (30), p.3764-3772 [Periódico revisado por pares]

Netherlands: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
Material Type:
Artigo 		Adicionar ao Meu Espaço

Advances in gene-based vaccine platforms to address the COVID-19 pandemic

Pushparajah, Deborah ; Jimenez, Salma ; Wong, Shirley ; Alattas, Hibah ; Nafissi, Nafiseh ; Slavcev, Roderick A.

Advanced drug delivery reviews, 2021-03, Vol.170, p.113-141 [Periódico revisado por pares]

Netherlands: Elsevier B.V

Texto completo disponível

Citações Citado por
3
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Stuart, Arabella S V ; Shaw, Robert H ; Liu, Xinxue ; Greenland, Melanie ; Aley, Parvinder K ; Andrews, Nick J ; Cameron, J C ; Charlton, Sue ; Clutterbuck, Elizabeth A ; Collins, Andrea M ; Darton, Tom ; Dinesh, Tanya ; Duncan, Christopher J A ; England, Anna ; Faust, Saul N ; Ferreira, Daniela M ; Finn, Adam ; Goodman, Anna L ; Green, Christopher A ; Hallis, Bassam ; Heath, Paul T ; Hill, Helen ; Horsington, Bryn M ; Lambe, Teresa ; Lazarus, Rajeka ; Libri, Vincenzo ; Lillie, Patrick J ; Mujadidi, Yama F ; Payne, Ruth ; Plested, Emma L ; Provstgaard-Morys, Samuel ; Ramasamy, Maheshi N ; Ramsay, Mary ; Read, Robert C ; Robinson, Hannah ; Screaton, Gavin R ; Singh, Nisha ; Turner, David P J ; Turner, Paul J ; Vichos, Iason ; White, Rachel ; Nguyen-Van-Tam, Jonathan S ; Snape, Matthew D

The Lancet (British edition), 2022-01, Vol.399 (10319), p.36-49 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
COVID-19 Vaccine: A comprehensive status report
COVID-19 Vaccine: A comprehensive status report
Material Type:
Artigo 		Adicionar ao Meu Espaço

COVID-19 Vaccine: A comprehensive status report

Kaur, Simran Preet ; Gupta, Vandana

Virus research, 2020-10, Vol.288, p.198114-198114, Article 198114 [Periódico revisado por pares]

Netherlands: Elsevier B.V

Texto completo disponível

Citações Citado por
5
SARS-CoV-2 vaccines for cancer patients: a call to action
SARS-CoV-2 vaccines for cancer patients: a call to action
Material Type:
Artigo 		Adicionar ao Meu Espaço

SARS-CoV-2 vaccines for cancer patients: a call to action

Corti, Chiara ; Crimini, Edoardo ; Tarantino, Paolo ; Pravettoni, Gabriella ; Eggermont, Alexander M.M. ; Delaloge, Suzette ; Curigliano, Giuseppe

European journal of cancer (1990), 2021-05, Vol.148, p.316-327 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine
Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine
Material Type:
Artigo 		Adicionar ao Meu Espaço

Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine

Desai, Sajjad ; Rathi, Niraj ; Kawade, Anand ; Venkatramanan, Padmasani ; Kundu, Ritabrata ; Lalwani, Sanjay K. ; Dubey, A.P. ; Venkateswara Rao, J. ; Narayanappa, D. ; Ghildiyal, Radha ; Gogtay, Nithya J ; Venugopal, P. ; Palkar, Sonali ; Munshi, Renuka ; Bavdekar, Ashish ; Juvekar, Sanjay ; Ganguly, Nupur ; Niyogi, Prabal ; Uttam, Kheya Ghosh ; Kondekar, Alpana ; Kumbhar, Dipti ; Mohanlal, Smilu ; Agarwal, Mukesh C. ; Shetty, Parvan ; Antony, Kalpana ; Gunale, Bhagwat ; Dharmadhikari, Abhijeet ; Deshpande, Jagdish ; Nalavade, Uma ; Sharma, Deepa ; Bansal, Anurag ; Tang, Yuxiao ; Flores, Jorge ; Kulkarni, Prasad S.

Vaccine, 2018-09, Vol.36 (37), p.5519-5523 [Periódico revisado por pares]

Netherlands: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study
Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study

Cohen, Dani ; Atsmon, Jacob ; Artaud, Cécile ; Meron-Sudai, Shiri ; Gougeon, Marie-Lise ; Bialik, Anya ; Goren, Sophy ; Asato, Valeria ; Ariel-Cohen, Ortal ; Reizis, Arava ; Dorman, Alexandra ; Hoitink, Carla W G ; Westdijk, Janny ; Ashkenazi, Shai ; Sansonetti, Philippe ; Mulard, Laurence A ; Phalipon, Armelle

The Lancet infectious diseases, 2021-04, Vol.21 (4), p.546-558 [Periódico revisado por pares]

United States: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
Material Type:
Artigo 		Adicionar ao Meu Espaço

From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

Guy, Bruno ; Barrere, Beatrice ; Malinowski, Claire ; Saville, Melanie ; Teyssou, Remy ; Lang, Jean

Vaccine, 2011-09, Vol.29 (42), p.7229-7241 [Periódico revisado por pares]

Netherlands: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Virus-like particle-based human vaccines: quality assessment based on structural and functional properties
Virus-like particle-based human vaccines: quality assessment based on structural and functional properties
Material Type:
Artigo 		Adicionar ao Meu Espaço

Virus-like particle-based human vaccines: quality assessment based on structural and functional properties

Zhao, Qinjian ; Li, Shaowei ; Yu, Hai ; Xia, Ningshao ; Modis, Yorgo

Trends in biotechnology (Regular ed.), 2013-11, Vol.31 (11), p.654-663 [Periódico revisado por pares]

Cambridge, MA: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix ™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children
An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix ™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children
Material Type:
Artigo 		Adicionar ao Meu Espaço

An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix ™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children

Knuf, Markus ; Pantazi-Chatzikonstantinou, Anna ; Pfletschinger, Ulrich ; Tichmann-Schumann, Irmingard ; Maurer, Hartwig ; Maurer, Lothar ; Fischbach, Thomas ; Zinke, Henrike ; Pankow-Culot, Heidemarie ; Papaevangelou, Vassiliki ; Bianco, Veronique ; Van der Wielen, Marie ; Miller, Jacqueline M

Vaccine, 2011-06, Vol.29 (25), p.4264-4273 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (89.433)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (91.568)
  2. magazinearticle  (1.008)
  3. Anais de Congresso  (145)
  4. Book Chapters  (49)
  5. Resenhas  (37)
  6. Web Resources  (2)
  7. Reports  (2)
  8. Livros  (2)
  9. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1964  (369)
  2. 1964Até1978  (1.556)
  3. 1979Até1993  (6.378)
  4. 1994Até2009  (30.122)
  5. Após 2009  (54.401)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (89.882)
  2. Japonês  (6.999)
  3. Francês  (2.108)
  4. Espanhol  (1.161)
  5. Português  (336)
  6. Chinês  (52)
  7. Norueguês  (36)
  8. Russo  (34)
  9. Africâner  (10)
  10. Alemão  (5)
  11. Coreano  (3)
  12. Holandês  (1)
  13. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.